甲泼尼龙治疗重症肌无力的疗效  

Therapeutic effect of methylprednisolone on myasthenia gravis

作　　者：董礼全[1] 徐东[1] 马春燕[2] 崔彬[2] 彭忠民[3] 

机构地区：[1]山东大学山东省立医院神经内科 [2]山东大学山东省立医院中心实验室 [3]山东大学山东省立医院胸外科,山东济南250021

出　　处：《中国新药与临床杂志》2007年第6期449-451,共3页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：目的:评价甲泼尼龙治疗重症肌无力(MG)的临床效果。方法:对大剂量甲泼尼龙冲击(MPPT)治疗的34例MC病人于治疗前及治疗后分别进行临床评分,乙酰胆碱受体抗体(AChRAb)滴度,CD4^+CD25^+调节性T细胞(CD4^+CD25^+Tr)数量检测。结果:MPPT治疗MG后,1wk时临床显效率56%,3 mo时临床显效率为79%,总有效率为91%。治疗3mo后血清AChRAb滴度无明显变化(P＞0．05),CD4^+CD25^+Tr百分率明显升高,与治疗前相比差别有非常显著意义(P＜0．01)。结论:甲泼尼龙治疗重症肌无力的疗效好,可促进CD4^+CD25^+Tr细胞比率升高,值得临床推广。AIM： To evaluate the therapeutic effect of methylprednisolone pulse therapy （MPPT） on myasthenia gravis （MG）. METHODS： Thirty-four patients with definite MG were treated by high dosage MPPT. Before and after treatment, the clinical scores, acetylcholine receptor antibody （AChRAb） titers, and the expression of CD4^＋CD25^＋Tr cells were measured. RESULTS. One week after MPPT treatment, the clinical therapeutic rate reached 56 % and increased to 79 % three months later, with total effective rate of 91%. AChRAb titers showed no markedly change （P 〉 0.05） The expression of CD4^＋CD25^＋Tr cells demonstrated high significant in comparing with that before the treatment （P〈 0.01 ） . CONCLUSION： The treatment effect of methylprednisolone therapy on myasthenia gravis is positively efficient with promotion of the expression of CD4^＋CD25^＋Tr cells and worthy to recommended clinically.

关 键 词：甲泼尼龙 重症肌无力 受体 胆碱能 T淋巴细胞 

分 类 号：R977.1[医药卫生—药品]